Physician

Aamina B Akhtar, MD

According to 2025 Medicare claims, Aamina Akhtar, MD (NPI: 1124095831) practices infectious disease in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from St. Louis, MO. This provider's primary affiliated billing organization is INFECTIOUS DISEASES PC (NPI: 1720055452; TIN: 431895029) and primary practice location at 63128-2106. Akhtar is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Akhtar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 162 traditional Medicare patients, billed 7,753 HCPCS/CPT codes, and received $74,033 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 258 prescription claims across 57 beneficiaries totaling $135,981 in drug costs, led by Biktarvy (Bictegrav/Emtricit/Tenofov Ala). Open Payments data shows 1 records totaling $17. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $378,849 to $74,033. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $118,117 and ending at $135,981. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	543	124,114	$378,849
2016	491	52,796	$379,621
2017	509	73,028	$321,926
2018	434	20,306	$225,332
2019	408	9,435	$205,861
2020	224	82,730	$127,348
2021	174	70,357	$70,414
2022	117	5,274	$43,075
2023	115	21,389	$53,456
2024	162	7,753	$74,033

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	109	358	$118,117
2016	114	377	$129,140
2017	105	400	$125,304
2018	96	374	$66,365
2019	91	349	$71,271
2020	58	242	$74,810
2021	47	231	$114,000
2022	39	196	$126,334
2023	48	224	$170,094
2024	57	258	$135,981

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	30	30	$131
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	32	34	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	30	68	$97
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	62	73	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	113	292	$60

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	13	390	$51,352
Isentress	Raltegravir Potassium	13	390	$25,439
Piperacillin-Tazobactam	Piperacillin Sodium/Tazobactam	29	191	$5,769
Vancomycin Hcl	Vancomycin Hcl	19	633	$3,862
Meropenem	Meropenem	12	81	$1,652

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$17	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aamina B. Akhtar, MD?

Tedicare shows public-source Medicare data for Aamina B. Akhtar, MD (NPI 1124095831), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aamina B. Akhtar, MD have ACO affiliation data?

Aamina B. Akhtar, MD is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Aamina B. Akhtar, MD?

Aamina B. Akhtar, MD is linked to INFECTIOUS DISEASES PC (billing NPI 1720055452) in the available physician profile data.

Does Aamina B. Akhtar, MD have Open Payments data?

Aamina B. Akhtar, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.